Oncomine Acute Myeloid Leukemia (AML) Panel – Targeted NGS Solution for AML Research

Description

The Oncomine Acute Myeloid Leukemia (AML) Panel is a highly targeted, next-generation sequencing (NGS) solution designed to deliver comprehensive genomic insights for the accurate characterization of acute myeloid leukemia. Developed to meet the demanding needs of clinical and translational research, this panel enables rapid, reliable detection of key genetic alterations associated with AML, empowering clinicians and researchers to make informed decisions with confidence.

What is the Oncomine AML Panel?

The Oncomine AML Panel is a highly sensitive and targeted NGS assay designed to detect mutations, fusions, and variants in key genes associated with acute myeloid leukemia. By identifying molecular drivers of the disease, this test enables clinicians to make informed decisions regarding treatment strategies, including targeted therapies and clinical trial eligibility.

Test Overview

• Test Name: Oncomine Acute Myeloid Leukemia (AML) Panel
• Sample Type: Peripheral blood or bone marrow aspirate
• Method: Next-Generation Sequencing (NGS) using Ion Torrent™ technology
• Turnaround Time: 10–14 working days (subject to sample quality and lab workflow)
• Genes Tested: Covers over 30 clinically relevant AML-associated genes including FLT3 , NPM1 , CEBPA , KIT , IDH1/IDH2 , RUNX1 , TP53 , DNMT3A , ASXL1 , KIT , JAK2 , KRAS , PTPN11 , and more

Why Choose This Test?

• Comprehensive Molecular Profiling: Detects single nucleotide variants (SNVs), insertions/deletions, and gene fusions critical in AML.
• Risk Stratification & Prognosis: Helps classify patients into favorable, intermediate, or adverse risk groups based on mutational status.
• Guidance for Targeted Therapies: Identifies actionable mutations such as FLT3-ITD , IDH1/IDH2 , and KIT that influence treatment choice.
• Supports Clinical Trial Enrollment: Provides detailed mutation data that may qualify patients for novel therapies and research studies.
• High Sensitivity & Accuracy: Utilizes the trusted Oncomine platform from Thermo Fisher Scientific for reliable results.

Features:

– Comprehensive coverage of 40 AML-relevant genes
– Detection of SNVs, indels, CNVs, and gene fusions in a single assay
– Sensitive detection of FLT3-ITD and KMT2A-PTD mutations
– Low DNA/RNA input requirements, ideal for limited clinical samples
– Optimized for FFPE and fresh/frozen tissue, as well as blood and bone marrow specimens
– Compatible with Ion GeneStudio™ S5 Systems for scalable throughput

Benefits:

– Enables precision oncology by identifying actionable mutations and prognostic markers
– Reduces the need for multiple sequential tests, saving time and resources
– Supports clinical research and trial enrollment with robust, reproducible data
– Enhances diagnostic confidence with high sensitivity and specificity

The Oncomine AML Panel delivers unmatched value by combining breadth of coverage, analytical performance, and operational efficiency. With this panel, you gain the power to unlock critical genomic information that can transform patient care and accelerate scientific discovery.